Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia by Stringaris, Kate et al.
836
ARTICLES
haematologica | 2014; 99(5)
Acute Myeloid Leukemia
Introduction
Chemotherapy induces remission in up to 80% of patients
presenting with de novo acute myeloid leukemia (AML).
However, disease free survival remains poor because of high
mortality from remission induction failure and relapse of the
majority of patients who achieve remission.1-3 In contrast to
the low curative potential of chemotherapy, the graft-versus-
leukemia (GVL) effect conferred by donor lymphocytes fol-
lowing allogeneic stem cell transplantation contributes to per-
manent disease eradication.4 Notably, natural killer (NK) cells
have a potent GVL effect in both HLA mismatched and
matched donor-recipient combinations,5-13 and rapid NK
recovery is associated with improved outcome and a greater
GVL effect after stem cell transplantation (SCT).14 NK cells are
an important component of the innate immune system, pro-
viding first-line defense against virus-infected cells and
tumors. NK cell function, which includes cytotoxicity and
cytokine release, is governed by a balance between inhibitory
receptors, notably the killer Ig-like receptors (KIRs) and the
heterodimeric C-type lectin receptor (NKG2A), and activating
receptors, in particular the natural cytotoxicity receptors
(NCR) NKp46, NKp30, NKp44 and the membrane protein
NKG2D.15-17
It is possible that NK cells also exert control over AML in
the autologous setting. NK cells are cytotoxic to AML blasts18
and higher NK-mediated cytotoxicity has been reported to
result in superior leukemia-free survival.19 While some studies
suggest that NK cells may be compromised in AML,20,21 only
limited data are available on the prognostic significance of
these abnormalities and whether such changes normalize
once patients achieve remission. To explore whether individ-
ual NK cell characteristics affect outcome in patients with
AML, we examined NK phenotype and function in newly
diagnosed AML patients at presentation and following remis-
sion induction (CR) using age-matched healthy controls. 
We found that NK cells in AML blood at presentation have
an abnormal phenotype with downregulation of the activat-
ing receptor NKp46 and upregulation of the inhibitory recep-
tor NKG2A. We also identified impaired cytotoxic and effec-
tor cytokine function which partially corrected in remission,
and could be induced in vitro in NK cells of healthy controls by
co-incubation with AML blasts. These changes predicted out-
come of remission-induction chemotherapy. Our findings
indicate that, in patients with AML, an immuno-editing
process induced by AML blasts limits NK cell control of
leukemia and that abnormal NKG2A and TNF-α production
predicts response to treatment for AML.
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The majority of patients with acute myeloid leukemia will relapse, and older patients often fail to achieve remis-
sion with induction chemotherapy. We explored the possibility that leukemic suppression of innate immunity
might contribute to treatment failure. Natural killer cell phenotype and function was measured in 32 consecutive
acute myeloid leukemia patients at presentation, including 12 achieving complete remission. Compared to 15
healthy age-matched controls, natural killer cells from acute myeloid leukemia patients were abnormal at presen-
tation, with downregulation of the activating receptor NKp46 (P=0.007) and upregulation of the inhibitory recep-
tor NKG2A (P=0.04). Natural killer cells from acute myeloid leukemia patients had impaired effector function
against autologous blasts and K562 targets, with significantly reduced CD107a degranulation, TNF-α and IFN-g
production. Failure to achieve remission was associated with NKG2A overexpression and reduced TNF-α produc-
tion. These phenotypic and functional abnormalities were partially restored in the 12 patients achieving remission.
In vitro co-incubation of acute myeloid leukemia blasts with natural killer cells from healthy donors induced sig-
nificant impairment in natural killer cell TNF-α and IFN-g production (P=0.02 and P=0.01, respectively) against
K562 targets and a trend to reduced CD107a degranulation (P=0.07). Under transwell conditions, the inhibitory
effect of AML blasts on NK cytotoxicity and effector function was still present, and this inhibitory effect was pri-
marily mediated by IL-10. These results suggest that acute myeloid leukemia blasts induce long-lasting changes in
natural killer cells, impairing their effector function and reducing the competence of the innate immune system,
favoring leukemia survival.
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Methods
Patient consent was obtained in accordance with the
Declaration of Helsinki. The local ethics board approved the study
(NREC ref. 10/H0711/16).
Peripheral blood (PB) samples were collected prospectively from
September 2009 to January 2012 from 32 consecutive AML
patients at presentation and compared with paired remission sam-
ples in 12 patients who achieved complete remission post
chemotherapy, and with PB samples from age-matched healthy
controls (n=15). All samples underwent Ficoll density separation
(Organon-Teknika, USA), freezing and storage in liquid nitrogen.
Surface receptor phenotyping
Cell surface analysis was performed with a BD FACS Calibur
flow cytometer (BD Biosciences, Oxford, UK) and FlowJo soft-
ware (Tree Star, San Carlos, CA, USA). PBMC were immune-
stained with CD3 and CD56 antibodies to identify the NK popu-
lation (CD56+, CD3–) and CD13, CD33 and CD34 antibodies to
exclude AML blasts. NK were characterized for surface expression
of NKp30, NKp44, NKp46, NKG2A, NKG2D, KIR2DL1/S1,
KIR2DL2/S2, KIR3DL1 and Pan KIR. AML blasts were character-
ized for expression of NK ligands: DR4/5, HLA-A, B, C, MICA/B,
HLA-E and Fas. Where cells were available, experiments were per-
formed in triplicate. Controls for AML blast phenotyping included
healthy-donor PBMC and Hela cells.
Cytotoxicity studies
AML blasts were separated from PBMC on a Robosep instru-
ment (STEMCELL, Grenoble, France) using a monoclonal anti-
body cocktail against CD33, CD34, CD123 and CD36 (StemSep,
France, modified from Le Dieu et al.22). Samples were checked to
ensure a minimum purity of 90% and rested overnight in
RPMI/20%FCS. 
PBMC were incubated with target cells for 5 h at an optimized
effector: target ratio of 1:1 based on percentage of NK frequency
in PBMC. Experiments were performed in triplicate based on sam-
ple availability. Targets for cytotoxicity studies included the K562
cell line (grown in RPMI/FCS) and autologous AML blasts. PBMC
were incubated without targets as the negative control and stimu-
lated with PMA (50 ng/mL) and ionomycin (2 mg/mL, Sigma
Aldrich) as positive controls. 
Optimizing a previously-published23 protocol, CD107a and Fas
Ligand antibodies, monensin (BD GolgiStopTM) and BFA
(Brefeldin A, Sigma, UK) were added to the cultures at incubation
onset. Cells were washed and stained with CD3, CD56 and KIR
antibodies, fixed/permeabilized (BD Biosciences, UK) and stained
with IFN-g and TNF-α antibodies. Cells were analyzed on a BD
LSRFortessa flow cytometer.  
Co-culture of healthy NK cells with leukemia cells
Healthy-donor NK cells were negatively selected (Miltenyi
Biotec, Germany) then cultured in 96-well plates at 250,000
cells/well for 24 h, with or without primary AML blasts or in tran-
swell devices at an NK:blast ratio of 10:1 or 1:1. Paired experi-
ments were performed overnight with or without 100 IU/mL rhIL-
2 (Proleukin, Chiron, Emeryville, CA, USA) to assess if any func-
tional or phenotypic NK abnormalities induced by AML blasts
could be reversed by IL-2. NK cells were then analyzed for cell sur-
face receptor expression by flow cytometry, and for cytotoxicity
and effector cytokine production against K562 leukemia cell tar-
gets. After centrifugation, supernatant from the co-culture experi-
ments were evaluated for production of the immunomodulatory
cytokines TGF-β and IL-10 by enzyme-linked immunosorbent
assay (ELISA) according to the manufacturer's instructions using
Human TGF-beta1 Platinum ELISA (ebiosciences) assay and
OptEIA human IL-10 ELISA (BD Bisosciences). Cytokine concen-
trations in supernatants were expressed as mean+standard devia-
tion of triplicates.
Indoleamine 2,3-dioxygenase expression and activity 
Human primary AML cells were tested for IDO mRNA expres-
sion by PCR.24 AML cells (1x105) were cultured in RPMI complete
medium with 106/mL allogeneic NK cells for 24 h. Then, NK cells
were collected and their effector function tested against K562
leukemia targets (ratio 1:1).
Results
Patients’ characteristics
Natural killer cells from AML patients were analyzed
from 32 consecutive patients at presentation and follow-
ing complete remission in 12 patients for whom remission
samples were available. Results were compared with 15
age-matched healthy controls. Patients’ characteristics are
detailed in Table 1,25 and include 16 with primary AML, 14
with AML secondary to antecedent hematologic disease,
and 2 with therapy-related AML. Median age was 61
years (range 21-87 years). Patients were treated with a
combination of daunorubicin (50-60 mg/m2 x 3 doses over
5 days) and cytarabine (100 mg/m2 x 20 doses over 10
days). In 3 patients, serial PBMC samples were taken after
each course of consolidation chemotherapy and at later
time points, as detailed. Patients received standard sup-
portive care with antifungal, anti-viral and antibiotic ther-
apy as appropriate. 
NK surface receptor phenotype is abnormal in AML 
and favors NK inhibition
We analyzed by flow cytometry the surface expression
of NK receptors including NCRs, KIRs and C-type lectins
on NK cells from 32 AML patients at diagnosis compared
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Table 1. Patients’ characteristics.
                                                                                               N. (%)
N. patients                                                                                                   32
Median age in years (range)                                                           61 (21-87)
Sex ratio (M:F)                                                                                         1.7:1
Cytogenetic risk group 
(European Leukemia Net definitions 2010)24                                       
Favorable                                                                                           3   (10%)
Intermediate                                                                                    17 (57%)
Adverse                                                                                              10 (33%)
Unknown/insufficient sample                                                              2
Primary AML                                                                                          16 (50%)
Secondary to MDS/MPD                                                                  14 (44%)
Secondary to previous therapy                                                      2   (6%)
Presenting WBC (x109/L)                                                                            
Raised (>11)                                                                                     14 (44%)
                                                                                                              (median 50, 
                                                                                                           range 16.1-126)
Normal (4-11)                                                                                    3   (9%)
Leukopenic (<4)                                                                              15 (47%)
Response to first-line treatment (DA 3+10)                                        
Complete remission                                                                          14 (44%)
Induction failure/partial remission/supportive care only         18 (56%)
with NK cells from 15 age-matched healthy controls
(Figure 1). Frequency of NKG2A-expressing NK cells was
significantly higher in AML at diagnosis compared to
healthy controls (mean 45%±4.2 vs. 32%±2.7; P=0.04)
(Figure 1C). Conversely, expression of the activating
receptor NKp46 was significantly lower in AML (MFI
187±15 vs. 266±q24 in healthy controls; P=0.007) (Figure
1D). We found no significant differences in the surface
K. Stringaris et al.
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Figure 1. NK surface phenotype is abnormal in AML compared to healthy controls. NK receptor surface expression in 32 patients with AML
at diagnosis compared with 15 healthy controls. (A) Gating strategy for AML-NK surface phenotype results.  AML-NK were gated on CD13,
CD33 and/or CD34–, CD3, CD56+ lymphocyte fraction of PBMCs. (B) Histograms showing NK surface phenotype in a representative AML
patient and healthy control. Open histograms represent isotype matched monoclonal antibody staining. Filled histograms represent staining
with specific PE-conjugated monoclonal antibodies. NK surface receptor phenotype of  (C) C-type lectins (D) NCRs (E) KIR (F) CD56 bright and
dim. Horizontal bars denote mean expression. Error bars denote standard deviation between individuals within group. KIR: killer
immunoglubulin receptor; NCR: natural cytotoxicity receptor; HC: healthy control; AML: acute myeloid leukemia.
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expression of CD56 bright and dim populations, NKG2D,
KIR, NKp30 or NKp44 on NK cells in AML patients com-
pared to healthy controls (Figure 1C-F). 
NK phenotypic abnormalities in AML are partially
restored following induction chemotherapy
We next examined whether alterations in activating and
inhibitory receptors normalized in patients achieving
remission (Figure 2). Following induction chemotherapy,
mean NKp46 expression increased significantly from
122±56 at presentation to 242±152 (P=0.012) (Figure 2A),
reaching values found in healthy controls. In contrast,
mean NKG2A expression continued to increase after
induction chemotherapy from 45%±24 at presentation to
61%±25 in remission (P=0.008) (Figure 2B). NKp46 and
NKG2A expression was assessed in 3 patients at diagnosis
(T0), after induction chemotherapy (T1), and following
repeated courses of consolidation chemotherapy (T2 and
T3). Interestingly, whereas NKp46 expression remained
within normal limits at T2 (MFI, 287) and T3 (MFI, 382),
NKG2A expression remained higher than in healthy con-
trols and continued to increase following consolidation
chemotherapy to 77% at T2 and 84% at T3 (P=0.05)
(Figure 2C).
NK phenotypic abnormalities are associated with
impaired cytotoxicity and effector cytokine function
AML-NK cells had significantly reduced CD107a
degranulation (5% vs. 11%; P=<0.001), TNF-α (1% vs.
3%; P=0.008) and IFN-g production (1% vs. 5%;
P=<0.001) compared to healthy controls (Figure 3A). We
also tested the ability of NK cells from AML patients to
exert effector function against autologous blasts. NK cells
from the majority of patients with AML at presentation
failed to mount significant cytotoxicity or effector
cytokine production against autologous AML blasts.
Since KIRs are important in both NK licensing and in
mediating NK cytotoxicity against AML,26-29 we compared
the effector function of KIR+ and KIR– subsets against K562
leukemia targets. As expected, KIR+ subsets displayed
greater cytotoxicity and effector function compared to
KIR- subsets in AML patients and in controls (Online
Supplementary Figure S1). Pan KIR+ NK cells derived from
AML patients at diagnosis displayed significantly less
cytotoxicity (CD107a degranulation, 6% vs. 12%;
P=0.003) and effector cytokine function (TFN-α produc-
tion 2% vs. 4%; P=0.026; IFN-g production 2% vs. 5%;
P=<0.001) against K562 leukemia targets compared to
control NK cells (Figure 3B). A similar pattern was seen in
KIR2DS1/DL1+, KIR2DS2/DL2+ and KIR3DS1/DL1
expressing NK subsets (Online Supplementary Figure S1).
Impaired cytotoxicity and effector function in AML-NK
cells was observed in both KIR+ and KIR– subsets with no
significant difference between different KIR expressing
NK subsets (Online Supplementary Figure S1). 
Interestingly, AML-NK cells were not significantly differ-
ent to NK from healthy donors in their ability to degranu-
late and produce TNF-α and IFN-g in response to stimula-
tion with PMA and ionomycin (Online Supplementary Figure
S2). This is in marked contrast to the reduced cytotoxicity
and effector function after stimulation by leukemic targets
(Figure 3). These data indicate that NK dysfunction in AML
is likely related to impaired NK receptor-ligand interaction,
without affecting protein kinase C dependent PMA- and/or
ionomycin-induced degranulation.30
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Figure 2. NK phenotypic abnormalities in AML are partially restored
following induction chemotherapy. (A) NKp46 expression is restored
following induction chemotherapy to levels consistent with those of
healthy controls. (B) NKG2A expression remains elevated. P values
report significance of paired t-tests comparing AML T0 (at presenta-
tion) and T1 (following induction chemotherapy) and unpaired 
t-tests comparing AML with healthy controls. (C) NKp46 and NKG2A
expression in a representative healthy control (left column) and
AML patient at serial time points (right column): diagnosis (T0), fol-
lowing induction chemotherapy (T1), following consolidation
chemotherapy #1 (T2), following consolidation chemotherapy #2
(T3). Horizontal bars denote mean expression. Error bars denote
standard deviation between individuals within group. HC: healthy
control; AML: acute myeloid leukemia. 
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Restoration of NK cytotoxicity and effector cytokine
function following induction chemotherapy
We assessed NK effector function and cytotoxicity in
the 12 patients who achieved remission following induc-
tion chemotherapy. AML-NK cells derived from patients
at remission tested against K562 leukemia target cells dis-
played CD107a degranulation and TNF-α production lev-
els comparable to that of healthy donor NK cells (9% vs.
K. Stringaris et al.
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Figure 3. NK cytotoxicity and effector function in AML patients at diagnosis compared to healthy controls. (A) Total NK (CD56+ CD3–) cytotoxicity
(CD107a degranulation), TNF-α and IFN-g production against K562 leukemia targets in 32 patients with AML and 15 healthy controls; (B) KIR
specific NK (CD56+ CD3– KIR+ ) cytotoxicity and effector cytokine function against K562 leukemia targets in 32 patients with AML and 15
healthy controls. Horizontal bars denote mean expression. Error bars denote standard deviation between individuals within group. HC: healthy
control; AML: acute myeloid leukemia.
Figure 4.  NK cytotoxicity and effector function at remission. (A) NK (CD56+ CD3–) CD107a degranulation and effector cytokine production
against K562 in 12 AML patients at remission compared to diagnosis and to 15 healthy controls. (B) NK CD107a degranulation and effector
cytokine function against autologous blasts in 12 AML patients at remission compared to diagnosis. P values report significance of paired T
tests comparing AML at T0 and remission and unpaired t-tests comparing AML with healthy controls. Horizontal bars denote mean expres-
sion. Error bars denote standard deviation between individuals within group. CR: complete remission; T0: diagnosis; HC: healthy control; AML:
acute myeloid leukemia.
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11%; P=0.4) and (2% vs. 3%; P=0.3), respectively. In con-
trast, IFN-g production, although significantly improved
from diagnosis (1% vs. 3%; P=0.009), only partially nor-
malized (3% at AML remission vs. 5% in healthy donors;
P=0.044) (Figure 4A). We assessed whether NK cells from
AML patients in remission recognized and mediated cyto-
toxicity against autologous blasts collected at diagnosis.
Although there was some response in a minority of
patients, NK cells from the majority of patients in remis-
sion failed to degranulate or produce effector cytokines
when stimulated with autologous AML blasts in vitro
(Figure 4B).
NK phenotypic abnormalities in AML correlate 
with impaired cytotoxicity and predict response
to chemotherapy
We next correlated NK surface receptor phenotype with
NK effector function and cytotoxicity, and response to
chemotherapy. We observed 2 groups of patients: a high
NKG2A-expressing and a low NKG2A-expressing group.
Those with higher NKG2A expression (> median 32.6%)
had impaired TNF-α production (P=0.003) (Figure 5A) and
were significantly less likely to achieve CR post
chemotherapy compared to those with lower NKG2A
expression (CR rate of 31% vs. 78%; P=0.041) (Figure 5C).
In contrast, whereas low NKp46 expression (< median
MFI) was associated with significantly reduced CD107a
degranulation and IFN-g production (P=0.004 and
P=0.047, respectively) (Figure 5B), we found no significant
correlation between NKp46 expression level at presenta-
tion and the probability of CR post induction chemother-
apy (data not shown), suggesting that NKG2A may be a
more clinically relevant marker for disease response than
NKp46. Interestingly, individuals with NKG2AhiNKp46lo
NK cells displayed the poorest NK effector function
against leukemia targets in vitro (Online Supplementary
AML-induced NK cell impairment predicts response 
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Figure 5. NK phenotypic and functional abnor-
malities at diagnosis and response to
chemotherapy. (A) NK cells in individuals with
low NKp46 expression (< median MFI) exhibit-
ed impaired cytotoxicity and IFN-γ production
against K562. (B) NK cells in individuals with
high NKG2A expression (> median) had
impaired TNF-α production against K562. (C)
High NKG2A expression (> median) at presen-
tation was associated with a poor response to
chemotherapy. (D) Low TNF-α production
against K562 at presentation (< median) was
associated with a poor response to
chemotherapy. Horizontal bars denote mean
expression. Error bars denote standard devia-
tion between individuals within group. P val-
ues denote significance of unpaired t-tests.
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Figure S3). NK effector function at diagnosis was associat-
ed with the probability of achieving CR after chemother-
apy. AML patients presenting with TNF-α production
above the median all achieved CR, compared to only 39%
(9 of 23) of patients with TNF-α production below the
median (P=0.041) (Figure 5D). 
Our findings that abnormal NK phenotype and effector
function at diagnosis can predict treatment response were
independent of other known AML prognostic factors such
as white blood count or karyotypic abnormality (data not
shown), suggesting that the effect of AML on NK cells
occurs irrespective of the patient’s AML disease character-
istics. 
NK cells co-cultured with AML cells display 
prompt impairment of cytolytic activity
Ex vivo selected NK cells from healthy controls were co-
incubated with primary AML blasts from patients at a 10:1
K. Stringaris et al.
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Figure 6. AML cells induce impairments in
NK effector function in vitro. (A) Effect of
AML blast co-culture on NK cell CD107a
degranulation, TNF-α and IFN-g production
against K562. (B) Representative FACS plots
showing the effect of co-incubating AML
blasts from 2 different patients on healthy
donor NK cell cytotoxicity and effector func-
tion are presented. After 24 h of healthy
donor NK co-culture with primary AML blasts
(ratio of 10:1) + IL-2 (200 iU/mL), the effec-
tor function of NK cells was assessed against
K562 leukemia targets (ratio 1:1). Plots are
gated on CD56+CD3– NK cells. (C) A dose
effect with increasing concentrations of
blasts exhibiting greater inhibition of healthy
NK function. 
A
B
C
NKG2A
CD
56
+
CD
3–
[%
]
NK+IL-2
19.0%
54.6% 18.3% 25.7%
42.7% 11.8% 13.4%
23.3% 11.4% 17.3%
31.7%
NK+IL-2 + AML blasts E:T ratio 1:1
NK+IL2
P=0.07
CD
10
7a
+
CD
56
+
CD
3–
[%
]
TN
Fα
CD
56
+
CD
3–
[%
]
IF
Ng
CD
56
+
CD
3–
[%
]
NK
+IL
-2
NK
+IL
-2+
AM
L B
las
t
NK
+IL
-2+
AM
L B
las
t
NK
+IL
-2+
AM
L B
las
t
NK
+IL
-2
NK
+IL
-2
P=0.02 P=0.01
NK+IL2+
blasts from
AML Patient 1
NK+IL2+
blasts from
AML Patient 2
CD56+ CD3– CD56+ CD3– CD56+ CD3–
CD107a TNFα IFNg
SSC
100
80
60
40
20
0
100
80
60
40
20
0
100
80
60
40
20
0
ratio for 24 h and their phenotype assessed in 4 independ-
ent experiments. There was no significant difference in
the expression of NKG2A or NKp46 in control NK cells
after co-culture with leukemia cells in the presence or
absence of IL-2 (200 iU/mL) compared to NK cells incubat-
ed for 24 h in the absence of AML blasts +/- IL-2 (200
iU/mL) (data not shown). The effect of AML blasts on cyto-
toxicity and effector function of peripheral blood NK cells
from 3 healthy controls was then tested. After 24 h co-
incubation of NK cells with primary AML blasts (at a ratio
of 10:1) in the presence or absence of IL-2 (200 iU/mL), NK
cells were purified and their effector function was
assessed against K562 leukemia targets. Co-incubation of
NK cells with AML blasts for 24 h resulted in upregulation
of NKG2A expression, associated with significant impair-
ment in NK cytotoxicity and effector function with
marked reduction in TNF-α production (P=0.02), IFN-g
production (P=0.01), and a trend to reduced CD107a
degranulation (P=0.07) against K562 leukemia targets
(Figure 6A-C). In 2 experiments, sufficient patient material
was available to test the dose effect of AML blasts on NK
dysfunction. NK cells were co-incubated with AML blasts
at two ratios of 1:1 and 10:1. NK effector abnormalities
were even more pronounced following co-incubation
with AML blasts at the higher ratio of 1:1 for 24 h (Figure
7A and B).  
In clinical protocols of NK adoptive therapy, systemic
IL-2 is administered to support NK expansion. We also
examined whether IL-2 can reverse the immune-editing
effects of AML blasts on NK cells. A similar pattern of NK
inhibition was seen in the presence of IL-2, indicating that
IL-2 alone cannot reverse AML-induced NK dysfunction.
IL-10, but not TGF-β or indoleamine 2,3-dioxygenase,
are involved in AML-mediated modulation of NK activity
To investigate the mechanisms responsible for the
inhibitory effects of AML blasts on NK function, co-cul-
ture experiments were performed in transwells. As shown
in Figure 8A, under transwell conditions, the inhibitory
effect of AML blasts on NK cytotoxicity and effector func-
tion was still present. These results suggested that AML
blasts constitutively release soluble factor(s) capable of
interfering with NK effector function. In an attempt to dis-
cover the soluble factor responsible for this phenomenon,
supernatants from co-culture experiments were evaluated
for production of the immunomodulatory cytokines TGF-
β and IL-10, previously shown to induce expression of
CD94/NKG2A on the surface of NK cells,31 and play a role
in the escape of tumor cells from NK-mediated immune
surveillance.32 Although, we did not detect significant lev-
els of TGF-β in the supernatants collected from NK-AML
co-cultures, IL-10 levels were significantly increased in the
supernatants collected from NK-AML co-cultures after 24
h of culture, irrespective of whether cells were in direct
contact or separated by a transwell membrane (Figure 8B).
Interestingly, the greatest degree of AML-induced NK dys-
function was seen in co-cultures with the highest levels of
IL-10, which may reflect distinct immunosuppressive
properties of the leukemic blasts from patients with vary-
ing subtypes of AML.
Recent studies suggest that abnormal expression of the
immunosuppressive tyrosine-converting enzyme IDO
may be an important mechanism in melanoma-induced
NK dysfunction.33 To investigate whether IDO may also
play a part in AML-induced NK impairment, we measured
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Figure 7. (A) FACS plots
showing greater inhibition
of NK effector function
when healthy NK were
exposed to higher concen-
trations of blasts. (B)
Analysis of the effect of
AML blast co-culture on
the expression of NKG2A. 
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IDO expression in AML blasts from patients at diagnosis.
As previously observed, IDO was over-expressed in blasts
from a subset of patients. We next co-cultured NK cells
with AML blasts from patients with high versus no
expression of IDO for 24 h. We found no correlation
between the inhibitory effect of AML blasts on NK func-
tion and IDO expression (Online Supplementary Figure S4).
Taken together, these studies support a role for IL-10, but
not TGF-β or IDO, in AML-mediated modulation of NK
activity.
Discussion
In this study, we showed that the NK cells of patients
presenting with AML have phenotypic abnormalities,
with increased expression of the inhibitory receptor
NKG2A and downregulation of the activating receptor
NKp46. Following remission induction chemotherapy,
NKp46 expression, but not NKG2A, normalized. These
changes were associated with impaired NK effector func-
tion and cytotoxicity, and were induced in normal NK
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Figure 8. (A) Healthy donor NK cells were cultured for 24 h in IL-
2 (200 iU/mL), either alone or with primary AML blasts at a
1:10 or 1:1 ratio in the same well (NK + AML) or in transwell
devices and effector function of NK cells was assessed against
K562 leukemia targets (ratio 1:1). Plots are gated on
CD56+CD3– NK cells. (B) After centrifugation, supernatant from
the co-culture experiments were evaluated for production of
the immunomodulatory cytokines TGF-β and IL-10 by enzyme-
linked immunosorbent assay (ELISA) according to the manu-
facturer's instructions using the Human TGF-beta1 Platinum
ELISA (ebiosciences) assay and OptEIA human IL-10 ELISA set
from BD Bisosciences. Cytokine concentrations in super-
natants were performed in duplicates.
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cells by incubating with AML blasts, suggesting that NK
cells are subject to immune-editing by AML cells. 
The natural cytotoxicity receptors (NCRs) are a group of
activating glycoprotein receptors restricted to NK cells.
Recently, a number of cellular ligands for the NCRs have
been reported. These include ligands expressed on the sur-
face of virally-infected cells as well as tumor cells.34-38
NCRs have been described as crucial receptors for target
cell recognition and induction of NK cell-mediated cyto-
toxicity towards cancer cells.39-41 In keeping with previous
reports, we found significant downregulation of NKp46
expression in patients with AML at presentation.20,21 In
contrast to the study by the Costello group,21 we did not
observe a reduction in the surface expression of NKp30.
Previous studies have reported distinct non-overlapping
activities of NKp46 and NKp30 in decidual NK (dNK) cells.
Moreover, NKp46-mediated dNK cytotoxicity was nega-
tively controlled by specific co-engagement of NKG2A
inhibiting receptor.42 Whether this is involved in the selec-
tive downregulation of NKp46 expression in NK-AML
cells remains to be determined. Our data support previous
reports of synergy among NK receptors and the require-
ment for a 2-stage process of activation and triggering for
target cell lysis.43-45
Another possible cause for this discrepancy may be due
to differences in phenotyping techniques. Because CD56 is
often aberrantly expressed on AML blasts, we first gated
out blasts expressing CD13, 33 or 34 to separate these from
NK-AML cells in our study. The Costello group21 defined
and excluded AML blasts using CD45high expression.
They also excluded patients with a presenting white blood
cell count of more than 50x109/L, whereas this population
comprised 16% (5 of 32) of our patients. Furthermore, NK
cell analysis in the study by the Costello group was per-
formed on freshly-selected NK cells or NK cells treated in
vitro with interleukin-2. In our study, PBMC collected from
individual patients were frozen and batched prior to analy-
sis to allow accurate assessment of the kinetics and compar-
ison of NK receptor expression over time. 
At presentation, NK-AML cells had impaired effector
function and cytotoxicity against autologous AML blasts
as well as MHC-class-I-deficient leukemia targets. As
expected, KIR-expressing NK cells exhibited more cyto-
toxicity and effector cytokine function against the MHC
class I deficient K562 cell line than their KIR-negative
counterparts, further supporting a role for KIR immuno-
genetics in shaping the immune response to leukemia.7,13
However, there were no significant differences in effector
function of specific KIR-expressing NK cell subsets against
K562. Our analysis of effector function of KIR-expressing
NK subsets was limited by a number of factors: not all the
monoclonal antibodies used could distinguish activating
and inhibitory KIR receptors. Furthermore, due to the sto-
chastic expression of KIR on NK cells, the gated popula-
tions were likely to co-express multiple KIR receptors. 
Altered NKp46 and NKG2A expression was associated
with impaired NK effector function against autologous
AML blasts, supporting a role for tumor editing of NKp46
and NKG2A. Interestingly, there was no significant differ-
ence in NK cytotoxicity between patients with primary or
those with secondary AML (Online Supplementary Figure
S5) suggesting that the process of immune-editing by
blasts is relevant in both de novo and secondary AML. 
We found that in AML patients achieving remission fol-
lowing chemotherapy, NK cells displayed normal NKp46
expression whereas NKG2A expression remained
increased. A similar observation was reported in
melanoma patients after chemotherapy.46 We hypothesize
that higher frequencies of NKG2A+ NK cells are induced
by AML cells as part of immune-editing to facilitate tumor
survival. Indeed, our in vitro studies confirmed that
NKG2A expression is up-regulated following 24 h of in
vitro co-incubation with AML blasts. 
Following remission induction, there was a complete
restoration of NK cytotoxicity and partial recovery of
effector cytokine production against K562 leukemia target
cells. However, autologous leukemic blasts remained
resistant to lysis by NK cells derived from patients at
remission, suggesting that AML cells have evolved a
mechanism of escape from NK-cell mediated recognition.
In assessing NK receptor ligands on AML blasts, we found
no significant downregulation of HLA class I expression.
However, our study was limited by the use of a pan class
I mAb and the expression of individual HLA class I mole-
cules could not be ascertained. We also assessed the
expression by AML of the “non-classical” HLA-E ligand of
NKG2A. Although HLA-E expression was down-regulat-
ed on leukemic blasts in some patients, there was no sig-
nificant association of HLA-E with NKG2A expression or
outcome (data not shown). Another possible explanation for
the failure of NK cells to recognize autologous blasts could
be downregulation of as yet unidentified NCR target cell
ligands on the surface of AML cells.20,47 Since remission
reversed some of the abnormal phenotypic and functional
changes in AML-NK cells, we explored the ability of pri-
mary AML blasts to modify NKp46 and NKG2A expres-
sion and effector function in healthy-control NK cells. Co-
culture of healthy-donor NK cells with AML blasts
induced upregulation of NKG2A and impaired NK effector
function and cytotoxicity. Moreover, transwell experi-
ments showed that this effect is independent of cell-to-cell
contact, suggesting that AML blasts may release soluble
factors to avoid NK-mediated killing. In this context, a
number of cytokines, growth factors, and enzymes syn-
thesized by tumor and/or stromal cells have been reported
to exert suppressive effects on cells involved in immune
responses.48 For example, a recent study suggested abnor-
mal expression of the immunosuppressive tyrosine-con-
verting enzyme IDO as a mechanism for reduced NK
cytotoxicity in melanoma patients,33 as well as impaired T-
cell function in AML.24 However, we failed to detect a sig-
nificant correlation between AML blast IDO expression
and NK-AML effector function. Similarly, we failed to
detect significant production of the immunomodulatory
cytokine TGF-β in the supernatants collected from NK-
AML co-cultures (data not shown). IL-10 has been shown to
mediate immunosuppression49 and a recent study suggests
that release of IL-10 by AML cells can directly diminish
granule mobilization, cytotoxicity, and interferon-γ pro-
duction of human NK cells.50 Accordingly, we found
increased levels of IL-10 in NK-AML culture supernatants,
which correlated with the degree of AML-induced NK
dysfunction. Taken together, these findings suggest that
while NK cells from healthy donors can exert anti-
leukemia effects, the release of soluble factors with
immunomodulatory properties such as IL-10 by AML
blasts may ultimately limit the immunotherapeutic bene-
fit of NK cell therapy.
In summary, in AML patients, increased frequency of
NKG2A-expressing NK cells and downregulation of the
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activating receptor NKp46 appear to alter the balance of
receptor signals towards inhibition of NK cells and are
associated with impaired lytic and effector function.
Increased frequency of NKG2A-expressing NK cells and
impaired TNF-α production are associated with failure to
achieve remission after induction chemotherapy. Our
studies identify a negative influence of AML cells on the
ability of the innate immune system to control leukemia
proliferation. This has implications for the ability of the
individual to achieve remission with standard induction
chemotherapy, while the degree of NK functional recov-
ery in remission may influence long-term survival.
Impaired TNF-α production and increased NKG2A
expression at diagnosis, therefore, represent new prognos-
tic markers for chemotherapy response in AML. Future
studies will seek to better define the prognostic signifi-
cance of NK phenotypic and functional markers in AML
treatment outcome and identify mechanisms through
which AML cells suppress NK cell function.
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